# Prometheus Diagnostic Services Sheet

## IBD

**PROMETHEUS® IBD sgi Diagnostic™ #1800**  
The first and only test that combines serologic, genetic and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test will help physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.

**PROMETHEUS® Crohn’s Prognostic #2001**  
Provides personalized serogenetic profile for each patient that quantifies their risk of developing complications over time.

## CELIAC

**PROMETHEUS® Celiac PLUS #6360**  
The most comprehensive test for celiac disease. Combines both the PROMETHEUS® Celiac Genetics & PROMETHEUS® Celiac Serology.

**PROMETHEUS® Celiac Genetics #6260**  
Analyzes a patient’s genetic profile for genes specifically associated with celiac disease. Advanced high-resolution DNA probe analysis of HLA-DQ Haplotypes allow for disease risk stratification depending upon which HLA genes are detected.

**PROMETHEUS® Celiac Serology #1155**  
A comprehensive serum antibody profile which includes deamidated gliadin IgA & IgG, anti-endomysial (EMA) IgA, anti-tissue transglutaminase IgA and total serum IgA.

## THIOPURINE MANAGEMENT

**PROMETHEUS® TPMT Genetics #3300**  
Helps classify patients as one of three genotypes allowing physicians to individualize dosing, identify patients in whom thiopurine therapy should be avoided, and help reduce the risk of leukopenia.

**PROMETHEUS® TPMT Enzyme #3320**  
Provides a quantitative analysis of a patient’s thiopurine methyltransferase (TPMT) enzyme activity level allowing physicians to individualize dosing, identify patients in whom thiopurine therapy should be avoided, and help reduce the risk of leukopenia.

**PROMETHEUS® Thiopurine Metabolites #3200**  
Testing assists physicians in optimizing ongoing dosing of thiopurine immunosuppressant therapy to reach and maintain therapeutic goal. Thiopurine metabolite testing also helps to identify drug metabolite levels that may lead to toxicity and some of the reasons for treatment failure.

## ADDITIONAL TESTS

**PROMETHEUS® FIBROspectrum™ II #4000**  
Testing can aid physicians in differentiating no/mild liver fibrosis from moderate-to-severe liver fibrosis in patients with hepatitis C, and may help reduce the number of liver biopsies required.

**PROMETHEUS® LactoTYPE® #6100**  
A genetics test to identify genetic variant C/T-13910 which is highly associated with adult-type hypolactasia. Testing assists physicians with stratifying patients with suspected lactose intolerance into those with a genetic predisposition and those whose underlying cause may be due to other disease potentially requiring further diagnostic workup.